person · Reporting owner
GOODWIN ROBERT ALLEN II
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Orthofix Medical Inc.OFIX · Entity 1975 | President Biologics | April 02, 2018 | April 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Orthofix Medical Inc.
Report date April 02, 2018 · Filed April 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,257 |
Reported balance
After 2018-04-02 transaction · row 1
1 source rowRow 1 · 2018-04-02 · Grant · Acquired 2,198 · Balance 22,257 F1: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.87 · Expires 2028-04-02 | Direct | 7,803 |
Reported balance
After 2018-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-04-02 · Grant · Acquired 7,803 · Balance 7,803 F2: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018. |
| Performance Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2021-04-02 | Direct | 4,396 |
Reported balance
After 2018-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-04-02 · Grant · Acquired 4,396 · Balance 4,396 F3: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 2, 2018 to April 2, 2021. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 2, 2018, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.
F2: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018.
F3: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 2, 2018 to April 2, 2021. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 2, 2018, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2018 Filed Apr 3, 2018 22:41 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantPerformance Share Units · Derivative | 4,396 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-023302 · doc4.xml · derivative · entry 3 GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,396 Underlying: Common Stock · 4,396 shares Expires 2021-04-02 F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as April 2, 2018 to April 2, 2021. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of April 2, 2018, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 22:41 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantStock Option (right to buy) · Derivative | 7,803 | $0.00 Strike: $56.87 | $0.00 |
DisclosureSEC source: 0001209191-18-023302 · doc4.xml · derivative · entry 2 GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,803 Underlying: Common Stock · 7,803 shares Expires 2028-04-02 F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 22:41 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 2,198 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-023302 · doc4.xml · nonDerivative · entry 1 GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,257 F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, April 2, 2018. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 20:27 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | Disposition to issuerCommon stock | 6,205 | $48.29 | $299,654.96 |
DisclosureSEC source: 0001209191-17-050387 · doc4.xml · nonDerivative · entry 1 GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,127 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.21 to $48.33, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| July 03, 2017 Filed Jul 10, 2017 22:03 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantPerformance Share Units · Derivative | 4,881 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044661 · doc4.xml · derivative · entry 3 GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,881 Underlying: Common Stock · 4,881 shares Expires 2020-07-03 F3 · derivative.exercise_date: Represents market-based vesting performance stock units ("PSUs") that will settle as common stock on a one-for-one basis. The performance period of the grant is defined as July 3, 2017 to July 3, 2020. The PSUs will vest based on the percentile rank of the Company's total shareholder return ("TSR") over the performance period in relation to the TSR of the specified index companies. The index companies are based upon the companies included within the S&P Healthcare Select Sector index as of July 3, 2017, the grant date. In the event that the Company's TSR ranks at the 75th percentile or greater for the performance period, 200% of the PSUs will vest. In the event that the Company's TSR ranks between the 50th percentile and the 75th percentile, 100-200% of the PSUs will vest and 50-100% of the PSUs will vest if the Company's TSR ranks between the 25th percentile and 50th percentile. No PSUs will vest if the Company ranks below the 25th percentile. Read SEC document |
| July 03, 2017 Filed Jul 10, 2017 22:03 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantStock Option (right to buy) · Derivative | 8,516 | $0.00 Strike: $46.10 | $0.00 |
DisclosureSEC source: 0001209191-17-044661 · doc4.xml · derivative · entry 2 GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,516 Underlying: Common Stock · 8,516 shares Expires 2027-07-03 F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017. Read SEC document |
| July 03, 2017 Filed Jul 10, 2017 22:03 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 2,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044661 · doc4.xml · nonDerivative · entry 1 GOODWIN ROBERT ALLEN II · CIK 0001669838 · President Biologics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,332 F1 · shares: Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 3, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.